webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

N-(2-(Benzo[d][1,3]dioxol-5-yloxy)ethyl)-4-Formylbenzamide

  CAS No.: 1226006-03-6   Cat No.: BADC-00541 4.5  

N-(2-(Benzo[d][1,3]dioxol-5-yloxy)ethyl)-4-Formylbenzamide is an aldehyde-functionalized ADC linker supporting efficient site-specific conjugation, enhancing antibody-drug conjugate stability and therapeutic performance.

N-(2-(Benzo[d][1,3]dioxol-5-yloxy)ethyl)-4-Formylbenzamide

Structure of 1226006-03-6

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C17H15NO5
Molecular Weight
313.3
Shipping
Room temperature

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
N-[2-(1,3-benzodioxol-5-yloxy)ethyl]-4-formylbenzamide
Canonical SMILES
C1OC2=C(O1)C=C(C=C2)OCCNC(=O)C3=CC=C(C=C3)C=O
InChI
InChI=1S/C17H15NO5/c19-10-12-1-3-13(4-2-12)17(20)18-7-8-21-14-5-6-15-16(9-14)23-11-22-15/h1-6,9-10H,7-8,11H2,(H,18,20)
InChIKey
USEULTRMSIEIIH-UHFFFAOYSA-N
Shipping
Room temperature

N-(2-(Benzo[d][1,3]dioxol-5-yloxy)ethyl)-4-Formylbenzamide is a chemical compound with a unique structure that incorporates a benzo[d][1,3]dioxole group, a well-known pharmacophore with various bioactive properties. The benzo[d][1,3]dioxole ring system has been extensively studied for its potential in drug design due to its ability to interact with multiple biological targets. When combined with the formylbenzamide group, this compound presents an exciting opportunity for the development of novel therapeutic agents, particularly in the fields of cancer treatment, enzyme inhibition, and drug discovery.

One of the primary applications of N-(2-(Benzo[d][1,3]dioxol-5-yloxy)ethyl)-4-Formylbenzamide lies in its potential as an anticancer agent. The benzo[d][1,3]dioxole structure is known for its ability to interact with enzymes and receptors involved in cancer cell signaling, such as kinases and growth factor receptors. The formylbenzamide component may also play a critical role in targeting specific cellular pathways that are dysregulated in cancer. By modulating these pathways, the compound could inhibit tumor growth and proliferation, offering a promising strategy for the treatment of various cancers, including breast, lung, and colon cancers. The selectivity provided by the unique structure could reduce off-target effects, making it a valuable candidate for further development as a targeted cancer therapeutic.

In addition to its potential as an anticancer agent, N-(2-(Benzo[d][1,3]dioxol-5-yloxy)ethyl)-4-Formylbenzamide could be explored as a modulator of enzyme activity, particularly in relation to enzymes involved in cell signaling and metabolism. The benzo[d][1,3]dioxole ring is known to exhibit inhibitory activity against various enzymes, such as protein kinases, which are often overactive in cancer cells. The formylbenzamide group may enhance the binding affinity of the compound to these enzymes, allowing for more effective inhibition. By selectively inhibiting enzymes involved in cancer cell growth and survival, this compound could offer a therapeutic approach for treating cancer and other diseases linked to abnormal enzyme activity, such as autoimmune disorders or inflammatory diseases.

Furthermore, N-(2-(Benzo[d][1,3]dioxol-5-yloxy)ethyl)-4-Formylbenzamide has significant potential in drug discovery and molecular biology research. Due to its distinctive structure, it could serve as a valuable tool for studying drug-receptor interactions and cellular signaling mechanisms. The compound can be labeled with fluorescent or radioactive markers to track its distribution within cells or tissues. This capability makes it an excellent candidate for developing molecular probes that could aid in high-throughput screening assays, providing researchers with critical insights into how small molecules interact with biological targets. This research could lead to the identification of more effective drug candidates for treating various diseases.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Py-MAA-Val-Cit-PAB-MMAE | Lys(MMT)-PAB-oxydiacetamide-PEG8-N3 | (2R,10S)-10-Benzyl-2-cyclopropyl-23-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-6,9,12,15,18-pentaoxo-3-oxa-5,8,11,14,17-pentaazatricosanoic acid | Mal-di-PEG-Val-Cit-PAB | N3-PEG3-VC-PAB-MMAE | Mal-PEG6-NHS | Boc-Phe-(Alloc)Lys-PAB-PNP | MPB-VC-PAB-DM1 | Cbz-Phe-(Alloc)Lys-PAB-PNP | Nα-Azido-Nβ-Boc-L-2,3-diaminopropionic acid | N-(2-(Benzo[d][1,3]dioxol-5-yloxy)ethyl)-4-Formylbenzamide
Send Inquiry
Verification code
Inquiry Basket